BRAF and non-small cell lung carcinoma: No clinical studies have evaluated the role of sorafenib in BRAF mutated NSCLC patients, and clinical trials on sorafenib in unselected patients with advanced NSCLC have demonstrated modest activity, with no survival advantage [7, 10].